7 Phase 3 Trial of an Oral CXCR4 Antagonist, Mavorixafor, for Treatment of Patients With WHIM Syndrome: Preliminary Results From Ongoing Open-Label Extension Period of Continuous Mavorixafor Treatment
Clinical Immunology（2024）
关键词
WHIM syndrome,Combined immunodeficiency,CXCR4 antagonist,Mavorixafor,Phase 3 clinical trial,Neutropenia,Lymphopenia,Neutrophil,Rare disease,Primary immunodeficiency
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要